Stock Analysis on Net

Cigna Group (NYSE:CI)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Cigna Group, consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (loss) (212) 1,107 1,449 1,510 1,306 1,198 2,778 1,572 1,198 1,133 1,635 1,476 1,171 4,142 1,398 1,760 1,189 984 1,354 1,410 1,372
Depreciation and amortization 741 765 766 755 749 735 726 759 717 743 734 731 715 713 702 694 693 927 913 914 897
Realized investment (gains) losses, net 1,836 34 14 (26) 56 81 95 319 (68) (68) (59) (1) (167) (32) (38) 88 (93) (51) (23) (10)
Deferred income tax benefit (102) (1,356) (96) (99) (108) (180) (133) (29) (138) (116) (24) (45) (35) (46) (81) (98) (161) 87 (159) (79) (162)
(Gain) loss on sale of businesses 19 1,478 21 73 (1,735) (4,203)
Debt extinguishment costs 10 131 14 185 2
Accounts receivable, net (2,687) 253 (772) (665) (479) 102 430 (1,786) (983) 1,196 (806) (1,813) (1,420) 1,314 (689) (1,065) (1,056) 458 (6) (769) (396)
Inventories 1,015 (1,228) 97 (303) 566 (759) (237) (281) 222 (702) 21 (123) 247 (509) 55 (146) 96 (512) 137 84 440
Reinsurance recoverable and Other assets 68 (820) 172 37 72 (365) 167 (242) 402 (193) 70 (513) (20) 635 (563) 199 (348) (265) 22 (349) 73
Insurance liabilities 532 (898) (245) 194 1,533 (690) 507 78 396 104 186 234 443 101 257 142 341 (15) 293 (63) 360
Pharmacy and other service costs payable 4,637 (220) 703 1,008 539 392 244 1,198 (74) 604 234 708 415 807 429 1,247 408 (402) (503) 269 444
Accounts payable and Accrued expenses and other liabilities (1,068) 2,144 699 (52) 690 1,349 359 (168) 34 1,334 232 (1,006) (637) 1,378 (662) 322 308 1,320 393 (461) 91
Other, net 61 208 18 133 104 244 96 48 (63) 240 (95) 104 84 129 81 243 144 302 68 106 83
Net changes in assets and liabilities, net of non-operating effects 2,558 (561) 672 352 3,025 273 1,566 (1,153) (66) 2,583 (158) (2,409) (888) 3,855 (1,092) 942 (107) 886 404 (1,183) 1,095
Adjustments to reconcile net income (loss) to net cash provided by operating activities 5,052 360 1,377 982 3,722 901 505 (328) 832 3,142 484 (1,772) (78) 152 (503) 1,514 698 1,809 1,107 (371) 1,820
Net cash provided by operating activities 4,840 1,467 2,826 2,492 5,028 2,099 3,283 1,244 2,030 4,275 2,119 (296) 1,093 4,294 895 3,274 1,887 2,793 2,461 1,039 3,192
Debt securities and equity securities 268 321 111 450 196 338 167 482 757 978 200 474 378 245 400 882 756 848 603 565 1,471
Proceeds from investments sold 268 321 111 450 196 338 167 482 757 978 200 474 378 245 400 882 756 848 603 565 1,471
Debt securities and equity securities 179 257 213 245 257 203 261 407 456 363 593 344 328 422 332 357 408 544 543 419 319
Commercial mortgage loans 4 100 4 78 4 25 4 4 65 53 31 24 72 5 4 5 5 25 5 80 89
Other sales, maturities and repayments, primarily short-term and other long-term investments 272 133 140 153 160 133 161 266 479 675 364 533 364 489 422 318 346 333 328 283 367
Investment maturities and repayments 455 490 357 476 421 361 426 677 1,000 1,091 988 901 764 916 758 680 759 902 876 782 775
Debt securities and equity securities (180) (329) (666) (545) (2,794) (299) (433) (778) (1,246) (811) (743) (1,019) (980) (1,448) (1,167) (976) (1,174) (935) (1,135) (1,124) (1,088)
Commercial mortgage loans (32) (24) (35) (59) (77) (25) (59) (94) (104) (129) (58) (42) (13) (86) (37) (89) (95)
Other, primarily short-term and other long-term investments (594) (314) (206) (308) (377) (454) (260) (424) (425) (786) (632) (499) (637) (490) (500) (554) (380) (539) (367) (459) (388)
Investments purchased or originated (806) (667) (907) (912) (3,171) (830) (693) (1,227) (1,730) (1,691) (1,479) (1,647) (1,617) (1,996) (1,709) (1,543) (1,554) (1,560) (1,539) (1,672) (1,571)
Property and equipment purchases, net (300) (365) (403) (397) (408) (345) (338) (324) (288) (304) (350) (258) (242) (319) (252) (256) (267) (310) (243) (303) (194)
Acquisitions, net of cash acquired (4) (443) 3 (1,836) (4) (135) (147) (6)
Divestitures, net of cash sold (14) 5 22 (3) 4,895 (57) (61) 5,592
Other, net (112) (215) (38) (36) (43) (137) (11) (16) (6) 46 (8) 59 (14) 37 (4) (1) (6)
Net cash (used in) provided by investing activities (495) (440) (1,337) (414) (2,983) (616) 4,446 (408) (324) 123 (710) (2,307) (717) 4,420 (938) (237) (269) (271) (304) (634) 475
Deposits and interest credited to contractholder deposit funds 43 40 31 51 45 43 37 41 43 21 36 49 47 254 240 262 267 224 233 251 247
Withdrawals and benefit payments from contractholder deposit funds (65) (84) (39) (52) (48) (59) (67) (45) (49) (29) (43) (61) (35) (243) (253) (228) (255) (252) (303) (291) (251)
Net change in short-term debt (364) (286) 1,301 192 (9) (8) (1,807) 219 (463) (658) 1,161 1,502 (1,030) (532) 1,545 (773) (180) (202) 142 427 (1,048)
Net proceeds on issuance of term loan 1,398
Repayment of term loan (1,400)
Payments for debt extinguishment (10) (126) (20) (192) (3)
Repayment of long-term debt (2,210) (2,887) (80) (500) (379) (4,199) (1,150) (2,099) (589) (4,209) (1,151) (600) (1,740) (1,000)
Net proceeds on issuance of long-term debt 4,462 1,491 (2) 4,262 (5) 3,470
Repurchase of common stock (4,022) (544) (624) (154) (962) (1,733) (3,500) (1,006) (1,368) (1,421) (2,611) (916) (2,794) (1,690) (1,028) (368) (956) (447) (674) (404) (462)
Issuance of common stock 181 74 54 29 30 72 100 124 93 25 11 86 204 137 10 76 153 123 31 17 53
Common stock dividend paid (401) (358) (362) (362) (368) (334) (341) (352) (357) (324) (330) (342) (345) (15)
Other, net (153) (92) (46) (139) (136) (117) 61 103 (70) 15 48 11 (35) (97) (97) (50) 84 1 (2) (33) (73)
Net cash used in financing activities (2,529) (1,250) (2,572) (435) (37) (2,636) (5,517) (916) (2,171) (2,371) (1,728) (62) (4,051) (4,721) (1,682) (312) (1,818) (1,707) (1,173) (1,773) (2,534)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash (9) 14 (7) 4 5 12 (18) (57) (23) (19) (19) (1) (26) 48 8 22 (37) 19 (17) 2 (12)
Net increase (decrease) in cash, cash equivalents and restricted cash 1,807 (209) (1,090) 1,647 2,013 (1,141) 2,194 (137) (488) 2,008 (338) (2,666) (3,701) 4,041 (1,717) 2,747 (237) 834 967 (1,366) 1,121

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Cigna Group net cash provided by operating activities decreased from Q3 2023 to Q4 2023 but then increased from Q4 2023 to Q1 2024 exceeding Q3 2023 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Cigna Group net cash (used in) provided by investing activities increased from Q3 2023 to Q4 2023 but then slightly decreased from Q4 2023 to Q1 2024.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Cigna Group net cash used in financing activities increased from Q3 2023 to Q4 2023 but then slightly decreased from Q4 2023 to Q1 2024 not reaching Q3 2023 level.